Solutions
Empowering Continuous Vision Care: Advanced 24/7 Remote Monitoring and Real-Time Physician Alert System for Patient-Driven Eye Health and Early Detection of Systemic Diseases
Pharmaco-Genetic Mapping™
RetinalGeniX DNA/RNA GPS™ laboratory home-use test kits and software platform
- The pharmacogenetic mapping solution could aid in the development and reassignment of existing drug therapies that may be successful in treating alternate but genetically matched systemic diseases.
- “Drug repositioning results in lower overall developmental expenses and risk assessments, as the efficacy and safety of the original drug have already been well-accessed and approved by regulatory authorities”(1)</sup)
- System facilitates rapid and timely data collection for immediate review
- Reporting of adverse drug reactions
- RESULT: Better drug selection, analysis, and validation
(1) Low, Z. Y., Farouk, I. A., & Lal, S. K. (2020). Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. Viruses, 12(9). https://doi.org/10.3390/v12091058.
24/7 In-Home/Remote Monitoring
24/7 real-time physician and patient alert High-Resolution Retinal remote monitoring retinal and eye imaging system
- Real-time high-resolution imaging and monitoring connects patients with the proprietary eye-specialty provider network and is available for patient/doctor use 24/7
- A patient remote monitoring imaging system with physician alert for the monitoring by patients themselves
- Once identified by their physician, continuous remote monitoring becomes possible and sight-saving
High-Resolution Retinal Mass Screening Device
Embracing the future of retinal care, this device is not just a tool but a partner in the quest to combat ocular diseases and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions. The cost-effective high-resolution retina mass screening device represents a groundbreaking leap in ocular health technology, meticulously engineered to enhance early detection and management of retinal disorders. Designed with precision, it offers unparalleled clarity and depth in retinal imaging, enabling healthcare professionals to conduct comprehensive screenings with ease and efficiency. This device integrates advanced optical systems and sophisticated software algorithms to deliver sharp, high-resolution images, revealing intricate details of the retina that are crucial for early diagnosis of conditions like macular degeneration, diabetic retinopathy, and glaucoma and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
RetinalGeniX's DNA/RNA GPS™
The system combines high-resolution retinal imaging and pharmacogenetic mapping to develop new therapeutics for sight-threatening and systemic diseases. It’s a unique platform for screening, monitoring, and data generation for early detection of systemic and ocular disorders.
The application is expected to allow patients to obtain their genetic systemic bio-markers privately, discreetly, and confidentially. The system is intended to identify, monitor, profile, and screen patients for ocular and systemic diseases including cardiovascular, stroke, diabetes, Alzheimer’s, dementia, Parkinson’s, at a fraction of the cost of existing methods.
This cost-effective approach also facilitates better drug development, and enables the expansion of early detection from specialized labs to 1,000’s of locations including hospitals, nursing homes, community care centers, schools, pharmacies, assisted living, walk-in clinics, doctors’ offices, ambulatory surgery centers, optical outlets, etc.
